You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 207681 - 207690 of 207731 results
  1. Immersive and Interactive VR Platform for Quantitative Telehealth Rehabilitation of Rare Diseases

    SBC: ALTEC, INC            Topic: 20

    To develop a multi-modal virtual reality environment for remote use, enabling physicians and healthcare providers to guide rare disease patient therapy while automatically obtaining crucial health metrics.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Patient Care Environment through Immersive Virtual Reality

    SBC: CFD RESEARCH CORPORATION            Topic: 20

    To develop an immersive VR environment where clinicians can interact with patients with rare diseases using virtual avatars.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. DEVELOPMENT OF SNOW CLEANING WITH SUPERCRITICAL CO2

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: 23

    A prototype instrument will be constructed to clean, sterilize, and enable fully viable reuse of tissue culture polystyrene (TCPS) vessels such as T-flasks.

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Epitope-directed monoclonal antibody production for mosquito immune cells (for malaria)

    SBC: LUNA LABS USA LLC            Topic: 118

    Luna Labs proposes to develop monoclonal antibodies (mAbs) for use in the identification and characterization of mosquito immune cells for immune responses and validation through various immunoassays and surface plasmon resonance (SRP). Since the project focuses on target proteins expressed in mosquito hemocytes that mediate innate cellular and humoral immunity to pathogens, and the antibodies pro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)

    SBC: QOOLABS INC            Topic: 118

    QooLabs proposes to generate high-affinity monoclonal antibodies against six immune cell targets of Syrian golden hamsters that are relevant to long-COVID research. Specifically, the Offeror proposes to produce recombinant proteins as immunogens for immunization of rabbits, to generate rabbit monoclonal antibodies using their proprietary method, and to validate the antibodies for use in long-COVID ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. SBIR TOPIC 107, PHASE II, TRANSCATHETER POTTS SHUNT

    SBC: TRANSMURAL SYSTEMS LLC            Topic: 107

    Phase II award for continued development of a catheter system to establish a non-surgical Potts Shunt (transcatheter pulmonary-to-aortic anastomosis) to treat refractory pulmonary artery hypertension.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. PROVIRAL SEQUENCING DRIVEN DEVELOPMENT OF ENHANCED IPDAV2 WITH GLOBAL HIV-1 GROUP M COVERAGE TO SUPPORT WORLDWIDE CURE AND CLINICAL TRIALS

    SBC: ACCELEVIR DIAGNOSTICS LLC            Topic: 78

    The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-b ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ""THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES""

    SBC: Intuitive Biosciences, Inc.            Topic: 115

    Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. ""MULTIPLEXED DROPLET DIGITAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES FOR HIV DIAGNOSIS""

    SBC: Fluid Discovery Inc            Topic: 115

    Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. ""A MULTIFUNCTIONAL POINT-OF-CARE PLATFORM TO DIFFERENTIATE HIV INFECTION FROM VACCINE INDUCED SEROPOSITIVITY""

    SBC: BAEBIES, INC.            Topic: 115

    Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government